Latest Biotech News

Electra Therapeutics closed a $183 million Series C to advance its lead program, ELA026, into pivotal clinical testing for secondary hemophagocytic lymphohistiocytosis (HLH) and to develop...

Flagship Pioneering launched Expedition Medicines with a $50 million commitment to develop a covalent‑binding small‑molecule discovery platform targeting cancer and immune diseases. The newly...

Presentations at ESMO highlighted two actionable developments: circulating tumor DNA (ctDNA) assays are demonstrating utility in guiding adjuvant therapy decisions and reducing overtreatment in...

Two independent multicenter efforts reported that genomic profiling can identify melanoma patients at very low risk of lymph‑node metastasis and could reduce the need for sentinel lymph node...

Researchers published advances in CRISPR‑associated transposons (CASTs) that improve targeted DNA integration activity and retain high on‑site specificity through high‑throughput screening and...

Moderna reported that its cytomegalovirus (CMV) mRNA vaccine missed primary efficacy goals in a Phase 3 study and the company will stop most development of the program. The firm said efficacy was...

Arcturus Therapeutics disclosed interim results from a Phase 2 study of ARCT-032, an inhaled mRNA therapy for Class I cystic fibrosis (CF), showing no meaningful improvement in forced expiratory...

Alector reported that a GSK-partnered antibody failed to slow disease progression in a Phase 3 dementia trial and the company will end work on the asset. Management announced a strategic...

Takeda Pharmaceutical agreed to a large licensing and co-development deal with China’s Innovent Biologics covering up to three immuno-oncology and ADC candidates, committing $1.2 billion upfront...

Electra Therapeutics raised $183 million in a Series C to fund a pivotal trial and expand its pipeline of immunology programs. The financing, led by Nextech and EQT Life Sciences and including...

10x Genomics filed patent infringement suits against Illumina in Delaware federal court, alleging the sequencing giant violated core single‑cell and spatial transcriptomics patents. The complaints...

Researchers at the Icahn School of Medicine at Mount Sinai introduced LongTrack, a long‑read sequencing and assembly pipeline that tracks microbial strains after fecal microbiota transplantation...

St. Jude researchers published an engineering study of CRISPR‑associated transposons (CASTs) that advances programmable, RNA‑guided DNA integration. The team built a dual genetic screen to measure...

Two advances signal fast‑moving innovation in cell therapy: a Nature Biotechnology paper described an epigenetic reprogramming platform that enables safe, simultaneous multi‑gene modulation in...

Two independent studies reported progress on genomic assays that predict sentinel lymph node metastasis in melanoma and could reduce the need for diagnostic nodal surgery. Mayo Clinic and...

Moderna announced that mRNA-1647, its cytomegalovirus (CMV) vaccine candidate, failed to meet efficacy in a pivotal Phase 3 trial and the company will stop most development of the program. The...

Alector disclosed that an antibody co‑developed with GSK failed to meet the trial’s clinical endpoints in a late‑stage dementia study, and the company will stop work on the asset. The negative...

Galapagos said it could not find a buyer for its cell therapy business and will wind down the unit, closing multiple global sites and eliminating roughly 365 positions. The company said nonbinding...

Takeda agreed to codevelop and commercialize up to three immuno‑oncology and ADC candidates from Innovent, paying $1.2 billion up front and preserving rights to large milestone payouts. The...

Sanofi reported that efdoralprin alfa—an experimental recombinant protein acquired in its Inhibrx buyout—met primary and key secondary endpoints in a Phase 2 study for alpha‑1 antitrypsin...